Q-omics provides the consensus-scored MKX profile across patient tissues and cancer cell-line models. MKX expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MKX is differentially expressed in 8, with the highest sampling consensus in BLCA. Additionally, MKX RNA expression shows 14,343 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, BLCA, and TGCT as cancer lineages where MKX shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MKX — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MKX survival associations across molecular data types. MKX RNA expression shows survival associations in the most cancer types (24), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MKX RNA expression–survival associations across cancer types. High MKX expression shows unfavorable associations in BLCA, UVM and KICH, but favorable associations in SKCM, LGG and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MKX RNA expression.
This table summarizes MKX tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MKX. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MKX shows lower tumor expression in BLCA, KIRC and LUSC and higher tumor expression in THCA, HNSC and KICH. The BLCA box plot shows higher MKX RNA expression in normal versus tumor tissue (log2 FC = −1.944, t-test p < 0.001).
This table shows molecular features associated with MKX in patient tissues and cancer cell lines. In patient samples, MKX shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MKX RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
